Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease (Q36922280)

17 August 2017

1 reference

title

Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease (English)

1 reference

17 August 2017

0 references

Timothy F Feltes

1

1 reference

17 August 2017

Henry M Sondheimer

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Biological Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

1471-1480

1 reference

Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Acute and long-term effects of infection by the respiratory syncytial virus in children with congenital cardiac malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Pro- and anti-inflammatory responses in respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

The current state of infection with respiratory syncytial virus in the setting of congenital cardiac malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Respiratory syncytial virus: the virus, the disease and the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Purification and characterization of the respiratory syncytial virus fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Lower glycemic response to sucrose in the diets of children with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

The therapeutic potential of monoclonal antibodies against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Monoclonal Antibodies to Human Respiratory Syncytial Virus and Their Use in Comparison of Different Virus Isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Guidelines for the use of palivizumab in infants and young children with congenital heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Palivizumab prophylaxis in haemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Economic analysis of palivizumab in infants with congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1471

10.1517/14712598.7.9.1471

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference